|
摘要: |
目的 采用meta分析对现已发表的氨苄西林/舒巴坦、头孢哌酮/舒巴坦和哌拉西林/舒巴坦治疗耐亚胺培南鲍曼不动杆菌(IRAB)的文献进行综合分析,科学比较哪种抗生素的治疗效果更好。方法 全面收集IRAB对氨苄西林/舒巴坦、头孢哌酮/舒巴坦和哌拉西林/舒巴坦耐药性研究的资料,根据严格的标准筛选纳入文献,用RevMan 4.2软件进行meta分析。 结果 共有9篇文献符合纳入标准。对氨苄西林/舒巴坦和头孢哌酮/舒巴坦的耐药性分析表明,IRAB对氨苄西林/舒巴坦(62.8%)的耐药性显著高于对头孢哌酮/舒巴坦的(44.7%)(P<0.001)。对氨苄西林/舒巴坦和哌拉西林/舒巴坦的耐药性分析表明,IRAB对氨苄西林/舒巴坦(70.7%)的耐药性显著低于对哌拉西林/舒巴坦的(95.2%)(P<0.001)。综合可得,IRAB对头孢哌酮/舒巴坦的耐药性最弱,对哌拉西林/舒巴坦的耐药性最强。结论 在IRAB的治疗中,头孢哌酮/舒巴坦的敏感性高于氨苄西林/舒巴坦和哌拉西林/舒巴坦,是较好的供选抗生素。 |
关键词: 耐亚胺培南鲍曼不动杆菌 耐药性 氨苄西林/舒巴坦 头孢哌酮/舒巴坦 哌拉西林/舒巴坦 meta分析 |
DOI: |
分类号: |
基金项目: |
|
Comparison of Activities of Three Sulbactam Complex Against Imipenem Resistant Acinetobacter Baumannii Infections: A Meta Analysis |
ZHOU Guangyao1,JIN Lingxiang1,FANG Peipei1,LI Jinqiang 2,DONG Xifen3
|
Abstract: |
OBJECTIVE A meta analysis was performed to decide whether ampicillin, cefoperazone or piperacillin in combination with sulbactam is better to cure imipenem resistant Acinetobacter baumannii in China. METHODS After a comprehensive electronic and manual searching according to our strict criterions, the related data were used for subsequent meta analysis using RevMan 4.2. RESULTS Total 9 papers were collected. The resistant rate of IRAB versus ampicillin/sulbactam (62.8%) was significantly higher than that of cefoperazone/sulbactam (44.7%) (P<0.001), and the resistant rate of IRAB versus ampicillin/sulbactam (70.7%) was significantly lower than that of piperacillin/sulbactam (95.2%) (P<0.001). That is to say, among the three sulbactam complex the resistant rate of IRAB versus cefoperazone/sulbactam was the highest, while the resistant rate of IRAB versus piperacillin /sulbactam was the lowest.CONCLUSION In the process of curing IRAB infections, cefoperazone/sulbactam is more sensitive than ampicillin/sulbactam and piperacillin/sulbactam, and thus is a better candidated antibiotic. |
Key words: imipenem resistant Acinetobacter baumannii resistance ampicillin/sulbactam cefoperazone/sulbactam piperacillin/sulbactam meta analysis |